Emerging therapies in narcolepsy-cataplexy. Export

@article{citeulike:783509, abstract = {In the past, narcolepsy was primarily treated using amphetamine-like stimulants and tricyclic antidepressants. Newer and novel agents, such as the wake-promoting compound modafinil and more selective reuptake inhibitors targeting the adrenergic, dopaminergic, and/or serotoninergic reuptake sites (ie, venlafaxine, atomoxetine) are better-tolerated available alternatives. The development of these agents, together with sodium oxybate (a slow-wave sleep-enhancing agent that consolidates nocturnal sleep, reduces cataplexy, and improves sleepiness), has led to improved functioning and quality of life for many patients with the disorder. However, these treatments are all symptomatically based and do not target hypocretin, a major neurotransmitter involved in the pathophysiology of narcolepsy. In this review, we discuss emerging therapies in the area of narcolepsy. These include novel antidepressant or anticataplectic, wake-promoting, and hypnotic compounds. We also report on novel strategies designed to compensate for hypocretin deficiency and on the use of immunosupression at the time of narcolepsy onset.}, address = {Howard Hughes Medical Research Institute, Stanford University School of Medicine, Stanford, CA, USA. mignot@leland.stanford.edu}, author = {Mignot, E. and Nishino, S.}, citeulike-article-id = {783509}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/16477963}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=16477963}, day = {1}, issn = {0161-8105}, journal = {Sleep}, keywords = {cataplexy, narcolepsy, review, sleep}, month = {June}, number = {6}, pages = {754--763}, posted-at = {2006-08-02 22:40:54}, priority = {2}, title = {Emerging therapies in narcolepsy-cataplexy.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/16477963}, volume = {28}, year = {2005} }

TY - JOUR ID - citeulike:783509 L3 - citeulike-article-id:783509 N2 - In the past, narcolepsy was primarily treated using amphetamine-like stimulants and tricyclic antidepressants. Newer and novel agents, such as the wake-promoting compound modafinil and more selective reuptake inhibitors targeting the adrenergic, dopaminergic, and/or serotoninergic reuptake sites (ie, venlafaxine, atomoxetine) are better-tolerated available alternatives. The development of these agents, together with sodium oxybate (a slow-wave sleep-enhancing agent that consolidates nocturnal sleep, reduces cataplexy, and improves sleepiness), has led to improved functioning and quality of life for many patients with the disorder. However, these treatments are all symptomatically based and do not target hypocretin, a major neurotransmitter involved in the pathophysiology of narcolepsy. In this review, we discuss emerging therapies in the area of narcolepsy. These include novel antidepressant or anticataplectic, wake-promoting, and hypnotic compounds. We also report on novel strategies designed to compensate for hypocretin deficiency and on the use of immunosupression at the time of narcolepsy onset. IS - 6 JF - Sleep SN - 0161-8105 AD - Howard Hughes Medical Research Institute, Stanford University School of Medicine, Stanford, CA, USA. mignot@leland.stanford.edu EP - 763 TI - Emerging therapies in narcolepsy-cataplexy. VL - 28 SP - 754 KW - cataplexy KW - narcolepsy KW - review KW - sleep AU - Mignot, E AU - Nishino, S PY - 2005/06/01/ UR - http://view.ncbi.nlm.nih.gov/pubmed/16477963 ER -